Reviews:
Circulating tumor cells in clinical research and monitoring patients with colorectal cancer
Metrics: PDF 1725 views | HTML 5909 views | ?
Abstract
Claudia Burz1,2, Vlad-Vasile Pop1, Rares Buiga2, Sur Daniel1,2, Gabriel Samasca1,3, Cornel Aldea3 and Iulia Lupan4,5
1Iuliu Hatieganu University of Medicine and Pharmacy, Department Of Immunology and Allergology, Cluj-Napoca, Romania
2Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania
3Emergency Hospital for Children, Cluj-Napoca, Romania
4BabeČ™-Bolyai University, Department of Molecular Biology and Biotehnology, Cluj-Napoca, Romania
5Institute of Interdisciplinary Research in Bio-Nano-Sciences, Cluj-Napoca, Romania
Correspondence to:
Vlad-Vasile Pop, email: [email protected]
Keywords: colorectal cancer; circulating tumor cells; metastasis; prognostic factor; survival
Received: April 27, 2017 Accepted: April 24, 2018 Published: May 11, 2018
ABSTRACT
Colorectal cancer remains a frequent disease to which screening and target therapy exist, but despite this is still marked by a high mortality rate. Even though radical surgery may be performed in many cases, patients relapse with metastatic disease. Circulating tumor cells were incriminated for tumor recurrence, that’s why vigorous research started on their field. Owning prognostic and predictive value, it was revealed their usefulness in disease monitoring. Moreover, they may serve as liquid biopsies for genetic tests in cases where tissue biopsy is contraindicated or cannot be performed. In spite of these advantages, they were not included in clinical guidelines, despite CellSearch and many other detection methods were developed to ease the identification of circulating tumor cells. This review highlights the implication of circulating tumor cells in metastasis cascade, intrinsic tumor cells mechanisms and correlations with clinical parameters along with their utility for medical practice and detection techniques.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25337